CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...